comparemela.com

Latest Breaking News On - Mary kwok - Page 1 : comparemela.com

FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma

The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.

United statesIrene ghobrialHelkha peredo pintoRavi madanSusan lattimoreMary kwokUniversity of washington school medicineDrug administrationJanssen pharmaceutical companies of johnsonJanssen biotech incDana farber cancer instituteOncologic drugs advisory committeeHarvard medical schoolBiologics licensing applicationJanssen biotechJanssen pharmaceutical companies

FDA Oncologic Drugs Advisory Committee Votes in Favor of Cilta-Cel as Early Treatment for Multiple Myeloma

The FDA’s ODAC sought to determine whether cilta-cel has a favorable benefit-risk profile for patients with multiple myeloma. The FDA’s ODAC unanimously voted that the potential benefits of cilta-cel outweigh its risks for its proposed indication in patients with multiple myeloma.

United statesRavi madanMary kwokSusan lattimoreIrene ghobrialHelkha peredo pintoJanssen pharmaceutical companies of johnsonDrug administrationOncologic drugs advisory committeeDana farber cancer instituteUniversity of washington school medicineJanssen biotech incHarvard medical schoolBiologics licensing applicationJanssen biotechJanssen pharmaceutical companies

vimarsana © 2020. All Rights Reserved.